Literature DB >> 15029207

Prognostic impact of p27KIP1 expression in cyclin D1 positive lymphoproliferative disorders.

R Letestu1, V Ugo, F Valensi, I Radford-Weiss, J Nataf, V Lévy, J G Gribben, X Troussard, F Ajchenbaum-Cymbalista.   

Abstract

Nodal mantle cell lymphoma (MCL) is a well-defined entity, but non-nodal leukemic cyclin D1 positive lymphoproliferative disorders have been reported and their relationship with MCL remains controversial and their prognosis heterogeneous. We prospectively studied the expression of cyclin D1 in CD5 positive leukemic B lymphoproliferative disorders at diagnosis and identified 65 cases overexpressing cyclin D1. We did not distinguish any clinical or biological criteria allowing one to identify a non-MCL group. Multivariate analysis identified age, anemia and p27kip1 expression as independent prognostic factors of survival. By univariate analysis, p27kip1 high expression proved to be the strongest predictor of prolonged survival. The median survival of p27 low expressors was 30 months, while it was not reached for p27 high expressors. A high level of p27 expression was often found associated with the absence of nodal involvement and the presence of somatic mutations, but neither of them was restricted to the p27 high expression group. In conclusion, we hypothesize that MCL and these cyclin D1 positive leukemic lymphoproliferative disorders represent a continuous spectrum of diseases. Determination of p27 expression level appears as a routine applicable test allowing identification of a subset of patients who could be considered for different therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15029207     DOI: 10.1038/sj.leu.2403337

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  5 in total

1.  Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma.

Authors:  Fanny Baran-Marszak; Mohand Boukhiar; Stéphanie Harel; Christelle Laguillier; Claudine Roger; Remy Gressin; Antoine Martin; Remi Fagard; Nadine Varin-Blank; Florence Ajchenbaum-Cymbalista; Dominique Ledoux
Journal:  Haematologica       Date:  2010-07-27       Impact factor: 9.941

2.  Clinicopathologic features of CDK6 translocation-associated B-cell lymphoproliferative disorders.

Authors:  Dong Chen; Mark E Law; Jason D Theis; Jeffrey D Gamez; Lynn B Caron; Julie A Vrana; Ahmet Dogan
Journal:  Am J Surg Pathol       Date:  2009-05       Impact factor: 6.394

3.  Potential effects of CRM1 inhibition in mantle cell lymphoma.

Authors:  Ke-Jie Zhang; Michael Wang
Journal:  Chin J Cancer Res       Date:  2012-12       Impact factor: 5.087

4.  LncRNA MALAT1 promotes development of mantle cell lymphoma by associating with EZH2.

Authors:  Xin Wang; Lalit Sehgal; Neeraj Jain; Tamer Khashab; Rohit Mathur; Felipe Samaniego
Journal:  J Transl Med       Date:  2016-12-20       Impact factor: 5.531

5.  CircCDYL Serves as a New Biomarker in Mantle Cell Lymphoma and Promotes Cell Proliferation.

Authors:  Mei Mei; Yingjun Wang; Qilong Wang; Yueyao Liu; Wenting Song; Mingzhi Zhang
Journal:  Cancer Manag Res       Date:  2019-12-03       Impact factor: 3.989

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.